Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies - Schedule of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Parenthetical) (Details)

v3.22.1
Summary of Significant Accounting Policies - Schedule of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Parenthetical) (Details) - shares
Mar. 31, 2022
Mar. 31, 2021
Anti-dilutive securities    
Warrant issued to purchase common stock 2,117,094 2,117,094
Private Placement    
Anti-dilutive securities    
Warrant issued to purchase common stock 2,828,125 2,828,125
Loan Agreement    
Anti-dilutive securities    
Warrant issued to purchase common stock 27,548 27,548
Second Draw on Loan Agreement    
Anti-dilutive securities    
Warrant issued to purchase common stock 17,389 17,389